Risk factor
Good trading liquidity
Profitability factor
Overvalued vs peers
About
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBITDA, overpric
Target Price
The average target price of 300558.SZ is 64 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
